1. Home
  2. LIXT vs NXTT Comparison

LIXT vs NXTT Comparison

Compare LIXT & NXTT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LIXT
  • NXTT
  • Stock Information
  • Founded
  • LIXT 2005
  • NXTT 2019
  • Country
  • LIXT United States
  • NXTT China
  • Employees
  • LIXT N/A
  • NXTT N/A
  • Industry
  • LIXT Biotechnology: Pharmaceutical Preparations
  • NXTT
  • Sector
  • LIXT Health Care
  • NXTT
  • Exchange
  • LIXT Nasdaq
  • NXTT NYSE
  • Market Cap
  • LIXT 4.1M
  • NXTT 3.5M
  • IPO Year
  • LIXT N/A
  • NXTT N/A
  • Fundamental
  • Price
  • LIXT $1.22
  • NXTT $0.29
  • Analyst Decision
  • LIXT
  • NXTT
  • Analyst Count
  • LIXT 0
  • NXTT 0
  • Target Price
  • LIXT N/A
  • NXTT N/A
  • AVG Volume (30 Days)
  • LIXT 31.7K
  • NXTT 363.4K
  • Earning Date
  • LIXT 03-24-2025
  • NXTT 05-19-2025
  • Dividend Yield
  • LIXT N/A
  • NXTT N/A
  • EPS Growth
  • LIXT N/A
  • NXTT N/A
  • EPS
  • LIXT N/A
  • NXTT 3.70
  • Revenue
  • LIXT N/A
  • NXTT $1,800,000.00
  • Revenue This Year
  • LIXT N/A
  • NXTT N/A
  • Revenue Next Year
  • LIXT N/A
  • NXTT N/A
  • P/E Ratio
  • LIXT N/A
  • NXTT $0.08
  • Revenue Growth
  • LIXT N/A
  • NXTT N/A
  • 52 Week Low
  • LIXT $1.02
  • NXTT $0.28
  • 52 Week High
  • LIXT $3.80
  • NXTT $6.66
  • Technical
  • Relative Strength Index (RSI)
  • LIXT 41.29
  • NXTT 27.15
  • Support Level
  • LIXT $1.15
  • NXTT $0.28
  • Resistance Level
  • LIXT $1.31
  • NXTT $0.32
  • Average True Range (ATR)
  • LIXT 0.11
  • NXTT 0.03
  • MACD
  • LIXT 0.03
  • NXTT 0.04
  • Stochastic Oscillator
  • LIXT 43.24
  • NXTT 13.33

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

About NXTT NEXT TECHNOLOGY HOLDING INC

Next Technology Holding Inc pursues two corporate strategies. One business strategy is to continue providing software development services, and the other strategy is to acquire and hold Bitcoin. It provides AI-enabled software development services to its customers, which include developing, designing, and implementing various SAAS software solutions for businesses of all types, including industrial and other businesses. Its bitcoin acquisition strategy generally involves acquiring bitcoin with its liquid assets that exceed working capital requirements, and from time to time, subject to market conditions, issuing debt or equity securities or engaging in other capital raising transactions to use the proceeds to purchase bitcoin.

Share on Social Networks: